Recent Updates
Recently added Catalysts
DXCM Positive Sentiment

Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time

Wednesday, October 7, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Dexcom, Inc. has announced the release date for its third quarter 2026 financial results, set for October 29, 2026. The earnings will be disclosed after market close, followed by a conference call at 4:30 p.m. Eastern Time. This call will be available via a webcast on the company's investor relations website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Dexcom is proactive in communicating its earnings release schedule.
  • The conference call provides an opportunity for investor engagement.
  • Management's transparency about financial performance is commendable.

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will

Frequently Asked Questions

When will Dexcom release its Q3 2026 financial results?

Dexcom will release its Q3 2026 financial results on October 29, 2026.

What time is the Dexcom Q3 2026 conference call?

The conference call will start at 4:30 p.m. Eastern Time.

Where can I access the Dexcom earnings call webcast?

The webcast link will be available on Dexcom's investor relations website.

What is the purpose of the conference call?

The conference call will review Dexcom's third quarter 2026 performance.

ShareAdd on Google
Tags: DXCM Dexcom earnings release financial results conference call NASDAQ:DXCM
Last updated: Oct 7, 2026

Biotech snapshot

Cash runway
$1947M liquidity · $0M/mo burn
Low dilution risk
Lead asset
The Seven Continuous Glucose Monitoring SystemPhase 1
Diabetes, Gestational →